About this trial
This study looks at a new medicine called AG-120 for people with certain types of blood cancers that have a specific genetic change called an IDH1 mutation. The trial has two parts. First, researchers will give different doses of AG-120 to find the best dose that people can tolerate. Then, they will give this best dose to more patients to see how well it works and how safe it is. The goal is to help patients with advanced blood cancers manage their condition better.
This study's ID number is NCT02074839. It is in Phase 1, which means it is looking at how well the treatment works and how safe it is. Around 291 people are expected to enroll in this study.
Who can join
Adults aged 18 and older can join. They must have a specific type of blood cancer with an IDH1 mutation. Participants need to be able to have regular blood tests and bone marrow samples. Some health conditions may disqualify a person, but the trial team will confirm who can participate.
Conditions
Relapsed or Refractory Acute Myeloid Leukemia (AML), Untreated AML, Other IDH1-mutated Positive Hematologic Malignancies, Myelodysplastic Syndromes
Age group
Adult, Older adult
The study team makes the final call on eligibility.
What happens in the study
Everyone in the study will receive AG-120. It is taken by mouth every day for 28 days at a time. Participants can continue taking it until their disease worsens or they experience unwanted side effects.
Where
This trial is running at 26 locations in the United States. 3 of them are currently recruiting.
MD Anderson Cancer Center
Houston, Texas
Medical University of South Carolina
Charleston, South Carolina
UT Southwestern Medical Center
Dallas, Texas
City of Hope
Duarte, California
Cleveland Clinic
Cleveland, Ohio
Cornell Cancer Center
New York, New York
Dana Farber Cancer Institute
Boston, Massachusetts
Duke Cancer Center
Durham, North Carolina
The first 8 of 26 sites are listed here. The registry record has the full list.